Early Heart Rhythm Treatment After Stroke in Atrial Fibrillation Patients
Tests early rhythm control therapy in adults with stroke and atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
Key facts
- Where
- Badalona, Barcelona, Majadahonda, Valencia, Valladolid, and Zaragoza, SpainSee the 8 sites
- Phase
- Phase 3
Where in Spain
- Hospital Germans Trias i PujolBadalona, SpainTaking people
- Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I SunyerBarcelona, SpainTaking people
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauBarcelona, SpainTaking people
- Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
- Hospital Universitario Puerta de Hierro de MajadahondaMajadahonda, SpainTaking people
- Hospital Clinico Universitario de ValenciaValencia, SpainTaking people
- Hospital Clínico Universitario de ValladolidValladolid, SpainTaking people
- Hospital Universitario Miguel ServetZaragoza, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universitätsklinikum Hamburg-Eppendorf
- Trial code
- NCT05293080EU 2025-521260-35-00
- Record updated
- 18 May 2026
- Original description
This study will determine whether early, comprehensive, rhythm control therapy prevents adverse cardiovascular outcome in patients with acute ischemic stroke and atrial fibrillation compared to usual care.Read full original descriptionShow less
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
This study will determine whether early, comprehensive, rhythm control therapy prevents adverse cardiovascular outcome in patients with acute ischemic stroke and atrial fibrillation compared to usual care.
Inclusion: Acute ischemic stroke in the previous four weeks, diagnosed by imaging (CT or MRI) or clinical diagnosis; Possibility to start the trial treatment within 4 weeks after stroke, and as soon as clinically justifiable; AF first detected ≤1 year prior to randomization; Informed consent.
Exclusion: Prior AF ablation or surgical therapy of AF; End-stage cancer or life-expectancy < 12 months due to other advanced co-morbid illness; Patients not suitable for rhythm control of AF due to cardiac conditions.